#Stockholm #Switzerland #stock sale #EQT VIII #Galderma

EQT Completes Sale of Shares in Galderma Group AG

EQT, a prominent investment firm, announced the successful completion of its share sale in Galderma Group AG, an event that underscores its strategic financial maneuvers. As of October 30, 2025, an affiliate of EQT VIII completed the placement of 20 million shares of Galderma, which brought in a total of approximately CHF 2.6 billion via an accelerated bookbuilding process.

Financial Overview of the Sale

The sale yielded approximately CHF 690 million for EQT, significantly enhancing its investment portfolio. This move reveals EQT's commitment to optimizing its financial strategies while contributing to the evolving landscape of the healthcare market.

This placement is not merely an isolated financial transaction; it reveals EQT's belief in Galderma's growth potential, considering the company specializes in dermatology and aesthetic solutions. Galderma has been an essential player in its sector, and EQT’s confidence in its continuing success is a positive indicator for stakeholders involved.

Coordination and Management Team

Six major financial institutions played critical roles in the transaction. Citigroup Global Markets, Goldman Sachs International, Jefferies, Merrill Lynch International, Morgan Stanley, and UBS were appointed as joint global coordinators and bookrunners. Their expertise ensured a seamless execution of the placement, marking a collaborative effort among leading investment banks.

Implications of the Sale

EQT’s decision to offload these shares could mean several things. Firstly, it opens up new avenues for EQT to allocate their substantial proceeds into other lucrative investments or existing portfolio companies. Secondly, this sale reflects market confidence as it was executed through a rapid and responsive process characterized by the accelerated bookbuilding method.

From a broader perspective, EQT's actions may influence market dynamics, particularly in the healthcare sector where investor confidence could catalyze further investments. As Galderma continues to navigate the dermatological market, EQT's backing may serve to bolster Galderma’s growth initiatives and innovative ventures moving forward.

Conclusion

In conclusion, EQT’s completed share sale in Galderma Group AG signifies a strategic financial move, fostering optimism for the firm's future endeavors. With a considerable influx of funds from this placement, EQT positions itself to capitalize on emerging opportunities in various sectors while reinforcing its influence in the investment landscape. Investors and market analysts alike will undoubtedly keep a close watch on both EQT and Galderma as they chart their paths in the coming months.